Brought to you by 
Lilly pays Icos $75mm up front to establish JV
29 Aug 2003
Executive Summary
Lilly will pay Icos (uf)$75mm up front to share 50-50 N. American and European profits from the sale of Icos' Phase II oral anti-impotence drug IC351. Lilly has also agreed to pay Icos an added $52.5mm to form a JV to develop the compound.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly pays Icos $75mm up front to establish JV
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice